Integrating proteomics into precision oncology.
genomics
precision oncology
proteomics
therapeutic decision making
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 03 2021
15 03 2021
Historique:
received:
29
06
2020
revised:
03
09
2020
accepted:
07
09
2020
pubmed:
20
9
2020
medline:
20
7
2021
entrez:
19
9
2020
Statut:
ppublish
Résumé
DNA sequencing and RNA sequencing are increasingly applied in precision oncology, where molecular tumor boards evaluate the actionability of genetic events in individual tumors to guide targeted treatment. To work toward an additional level of patient characterization, we assessed the abundance and activity of 27 proteins in 134 patients whose tumors had previously undergone whole-exome and RNA sequencing within the Molecularly Aided Stratification for Tumor Eradication Research (MASTER) program of National Center for Tumor Diseases, Heidelberg. Proteomic and phosphoproteomic targets were selected to reflect the most relevant therapeutic baskets in MASTER. Among six different therapeutic baskets, the proteomic data supported treatment recommendations that were based on DNA and RNA analyses in 10% to 57% and frequently suggested alternative treatment options. In several cases, protein activities explained the patients' clinical course and provided potential explanations for treatment failure. Our study indicates that the integrative analysis of DNA, RNA and protein data may refine therapeutic stratification of individual patients and, thus, holds potential to increase the success rate of precision cancer therapy. Prospective validation studies are needed to advance the integration of proteomic analysis into precision oncology.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1438-1451Informations de copyright
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.
Références
Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168:584-599.
Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333-339.
International Cancer Genome Consortium, Hudson TJ, Anderson W, et al. International network of cancer genome projects. Nature. 2010;464:993-998.
Haller F, Bieg M, Will R, et al. Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands. Nat Commun. 2019;10:368.
Barthelmess S, Geddert H, Boltze C, et al. Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol. 2014;184:1209-1218.
Chang MT, Asthana S, Gao SP, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34:155-163.
Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153:17-37.
Shumilov E, Flach J, Pabst T, et al. Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. Crit Rev Oncol Hematol. 2018;126:64-79.
de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300:765-767.
Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45:927-932.
Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell. 2019;24:65-78.
Szikriszt B, Poti A, Pipek O, et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol. 2016;17:99.
Centerwatch. 2018 FDA Approved Drugs.
Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554:189-194.
Horak P, Frohling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open. 2016;1:e000094.
Horak P, Klink B, Heining C, et al. Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer. 2017;141:877-886.
Leichsenring J, Horak P, Kreutzfeldt S, et al. Variant classification in precision oncology. Int J Cancer. 2019;145:2996-3010.
Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100-103.
Akbani R, Ng PKS, Werner HMJ, et al. A pan-cancer proteomic perspective on the cancer genome atlas. Nat Commun. 2014;5:3887.
Pierobon M, Wulfkuhle J, Liotta L, Petricoin E. Application of molecular technologies for phosphoproteomic analysis of clinical samples. Oncogene. 2015;34:805-814.
Khoury GA, Baliban RC, Floudas CA. Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Sci Rep. 2011;1:90.
Lu Y, Ling S, Hegde AM, et al. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol. 2016;43:476-483.
Wulfkuhle JD, Yau C, Wolf DM, et al. Evaluation of the HER/PI3K/AKT family signaling network as a predictive biomarker of pathologic complete response for patients with breast cancer treated with Neratinib in the I-SPY 2 TRIAL. JCO Precis Oncol. 2018;2 :1-20.
Kurnit KC, Dumbrava EEI, Litzenburger B, et al. Precision oncology decision support: current approaches and strategies for the future. Clin Cancer Res. 2018;24:2719-2731.
Nishizuka SS, Mills GB. New era of integrated cancer biomarker discovery using reverse-phase protein arrays. Drug Metab Pharmacokinet. 2016;31:35-45.
Pierobon M, Wulfkuhle J, Liotta LA, Petricoin EF. Utilization of proteomic technologies for precision oncology applications. In: Von Hoff DD, Han H, eds. Precision Medicine in Cancer Therapy. Cham: Springer; 2019:171-187.
Loebke C, Sueltmann H, Schmidt C, et al. Infrared-based protein detection arrays for quantitative proteomics. Proteomics. 2007;7:558-564.
Henjes F, Bender C, von der Heyde S, et al. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis. 2012;1:e16.
Mannsperger HA, Gade S, Henjes F, Beissbarth T, Korf U. RPPanalyzer: analysis of reverse-phase protein array data. Bioinformatics. 2010;26:2202-2203.
Johnson SC. Hierarchical clustering schemes. Psychometrika. 1967;32:241-254.
Kaufman L, Rousseeuw PJ. Introduction Finding Groups in Data. Hoboken, NJ: John Wiley & Sons; 1990:1-67.
Ward JH. Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963;58:236-244.
Pearson K. VII. Notes on regression and inheritance in the case of two parents. Proc Royal Soc London. 1895;58:240-242.
Wei T, Simko V. R package "corrplot": Visualization of a Correlation Matrix (Version 0.84), 2017.
Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 2000;60:3384-3388.
McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109-8115.
Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. J Natl Cancer Inst. 2018;110:704-713.
Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9-22.
Ng HY, Li J, Tao L, et al. Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR/ERK activation. Transl Oncol. 2018;11:1323-1333.
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133-150.
Prickett TD, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nature Genet. 2009;41:1127-1132.
Gomez-Suarez M, Gutierrez-Martinez IZ, Hernandez-Trejo JA, et al. 14-3-3 proteins regulate Akt Thr308 phosphorylation in intestinal epithelial cells. Cell Death Differ. 2016;23:1060-1072.
Heim D, Montavon G, Hufnagl P, Muller KR, Klauschen F. Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers. Genome Med. 2018;10:83.
Zhang Y, Yang L, Kucherlapati M, et al. A pan-cancer compendium of genes deregulated by somatic genomic rearrangement across more than 1,400 cases. Cell Rep. 2018;24:515-527.
Cheng J, Demeulemeester J, Wedge DC, et al. Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors. Nat Commun. 2017;8:1221.
Jameson GS, Petricoin EF, Sachdev J, et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat. 2014;147:579-588.
Pierobon M, Silvestri A, Spira A, et al. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. J Proteome Res. 2014;13:2846-2855.
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567.
Hu P, Liu Q, Deng G, et al. The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis. Sci Rep. 2017;7:42913.
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130-146.
Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227-232.
Mueller C, deCarvalho AC, Mikkelsen T, et al. Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. Cancer Res. 2014;74:818-828.
Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology Knowledge Base. JCO Precis Oncol. 2017;2017:1-16.
Griffith M, Spies NC, Krysiak K, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nature Genet. 2017;49:170-174.
Li J, Akbani R, Zhao W, et al. Explore, visualize, and analyze functional cancer proteomic data using the cancer proteome atlas. Cancer Res. 2017;77:e51-e54.
Satpathy S, Jaehnig EJ, Krug K, et al. Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020;11:532.